卵巢癌大型手术后静脉血栓栓塞与出血风险:标准住院期间与延长血栓预防持续时间对比
单中心回顾性前后队列研究纳入2018年1月至2020年12月250例卵巢癌大型手术患者,2019年7月前仅住院期间标准血栓预防,之后延长至28天。30天内VTE累积发生率4.8%、大出血0.8%;延长预防组VTE数值更低但无显著差异(HR 0.80,95%CI 0.25-2.52)。
要点
- 卵巢癌大型手术后30天内VTE累积发生率为4.8%(95%CI 2.1-7.4)。
- 延长血栓预防组VTE 4.2% vs 标准组5.3%,HR 0.80(95%CI 0.25-2.52),无显著差异。
- 两组大出血风险相似(0.8% vs 0.8%;HR 1.12,95%CI 0.07-17.89)。
核心结论
- 卵巢癌大型手术后VTE累积发生率较高,延长血栓预防安全且与数值更低的VTE风险相关,但差异无统计学显著。
研究设计与样本
- 单中心、回顾性、前后对照队列研究,纳入2018年1月至2020年12月接受大型手术的卵巢癌患者250例。
- 2019年7月前当地方案要求仅住院期间标准血栓预防;2019年7月起患者接受延长至28天的血栓预防。
- 采用Kaplan-Meier法估计术后30天内VTE和大出血的累积发生率及95%CI,并用Cox回归分析血栓预防持续时间与VTE的关联。
主要发现
- 250例中118例(47.2%)接受延长血栓预防,132例(52.8%)接受标准血栓预防。
- 随访期间12例发生VTE(累积发生率4.8%;95%CI 2.1-7.4),2例发生大出血(累积发生率0.8%;95%CI 0.0-1.9)。
- 延长血栓预防组VTE 5/118(4.2%)vs 标准组7/132(5.3%),HR 0.80(95%CI 0.25-2.52),无显著差异。
- 大出血风险两组相似:延长组1/118(0.8%)vs 标准组1/132(0.8%),HR 1.12(95%CI 0.07-17.89)。
关键数值与推荐
- 国际指南基于有限数据推荐延长血栓预防至最多28天。
- 本研究中延长血栓预防方案为28天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venous thromboembolism (VTE) is a frequent complication in patients with ovarian cancer after major surgery. Based on limited data, international guidelines recommend extended thromboprophylaxis for up to 28 days. OBJECTIVES: To assess the incidence of VTE and bleeding within 30 days following major surgery in patients with ovarian cancer and to evaluate the association between VTE and thromboprophylaxis duration. METHODS: This was a single-center, retrospective, "before-after" cohort study in patients with ovarian cancer undergoing major surgery. Before July 2019, the local protocol mandated a standard course of thromboprophylaxis during hospital stay only. From July 2019 onward, patients received extended thromboprophylaxis for 28 days. The cumulative incidences of VTE and major bleeding within 30 days after surgery were estimated using the Kaplan-Meier method, with 95% confidence intervals (CIs). Cox regression analysis was performed to evaluate the association between thromboprophylaxis duration and VTE incidence. RESULTS: Between January 2018 and December 2020, 250 women were included, of which 118 (47.2%) received extended and 132 (52.8%) standard thromboprophylaxis. During follow-up, 12 patients developed VTE (cumulative incidence, 4.8%; 95% CI, 2.1-7.4) and 2 major bleeding (cumulative incidence 0.8%; 95% CI, 0.0-1.9). Compared with standard thromboprophylaxis, VTE incidence was numerically lower with extended duration of thromboprophylaxis (5/118 [4.2%] vs 7/132 [5.3%]) but not significantly different (hazard ratio, 0.80; 95% CI, 0.25-2.52). The risk of major bleeding was similar in both groups (1/118 [0.8%] vs 1/132 [0.8%]; hazard ratio, 1.12; 95% CI, 0.07-17.89). CONCLUSIONS: The cumulative VTE incidence in patients with ovarian cancer following major surgery was considerable. Extended thromboprophylaxis was safe and associated with a numerically lower risk of VTE but not significantly different.
引用
- Wiegers HMG, Schaafsma M, Guman NAM, et al. Risk of venous thromboembolism and bleeding after major surgery for ovarian cancer: standard in-hospital versus extended duration of thromboprophylaxis. J Thromb Haemost. 2022. PMID: 36700503. doi:10.1016/j.jtha.2022.11.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。